Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06975436 · ClinicalTrials.gov registry record
Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis
A clinical trial of Bacterial Vaginosis and Candida Vaginitis, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- 738
- Enrollment target
- 10
- Study locations
NCT06975436 is a study of Bacterial Vaginosis and Candida Vaginitis that has completed, run by Hoffmann-La Roche. The registered enrollment target is 738 participants, above the 289-participant average among 15 other Bacterial Vaginosis trials with a reported enrollment target (155% higher). The trial reports 10 study locations across 7 states.
The verdict
NCT06975436, a study of Bacterial Vaginosis and Candida Vaginitis, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- 738 participants
- Enrollment target
- 10
- Study locations
Study Summary
In the clinical performance part of this study, prospectively acquired clinician-collected and clinician-instructed, self-collected vaginal swab specimens collected in cobas® PCR Media will be taken from a minimum of 500 symptomatic individuals with a clinical presentation consistent with vaginitis, vaginosis, or both. Additionally, a minimum of 100 asymptomatic individuals will also be enrolled in the study. The cobas® BV/CV assay amplifies and detects the deoxyribonucleic acid (DNA) of pathogens associated with bacterial vaginosis (BV) and candida vaginitis (CV). The BV results will be compared with the patient infection status (PIS) established by using 3 Food and Drug Administration (FDA)-cleared commercial assays, and the CV results will be compared with the PIS established with the use of culture plus MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight). The primary objective of the clinical performance study is to evaluate the performance (sensitivity and specificity) of cobas® BV/CV to determine the presence of BV and/or CV in the intended use patient population when being tested on cobas® 6800/8800 systems. The secondary objective is to evaluate the equivalency of cobas® BV/CV between the cobas® 5800 system and cobas® 6800/8800 systems.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST cobas® BV/CV test
- DIAGNOSTIC_TEST BD Max™ Vaginal Panel
- DIAGNOSTIC_TEST Cepheid Xpert Xpress MVP
- DIAGNOSTIC_TEST Hologic Aptima BV Assay
Study Locations (10)
California
- Matrix Clinical Research - Los Angeles
- M3 Wake Research - San Diego at Convoy - San Diego
North Carolina
- Eastern Carolina Women's Center - New Bern
- Unified Women's Clinical Research/Lyndhurst - Winston-Salem
Other
- Diagnostic Consultative Center "Ascendent" Ltd. - Sofia
- Centre Hospitalier Universitaire Vaudois (Chuv) - Lausanne
Colorado
- Red Rocks OBGYN - Lakewood
Florida
- Altus Research - Lake Worth
Missouri
- Washington University - St Louis
Texas
- Planned Parenthood Gulf Coast - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 738 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2025-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06975436
The ClinicalTrials.gov registry entry for NCT06975436 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 738 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 289-participant average among 15 other Bacterial Vaginosis trials with a reported enrollment target (155% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bacterial Vaginosis appearing as the primary indexed condition, and to 4 interventions - of which cobas® BV/CV test is the first listed.
NCT06975436 reports 10 study locations spanning 7 distinct geographic areas - top geographies include California, North Carolina, Other.
Frequently Asked Questions
What is clinical trial NCT06975436 about?
NCT06975436 is a clinical study titled "Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis". In the clinical performance part of this study, prospectively acquired clinician-collected and clinician-instructed, self-collected vaginal swab specimens collected in cobas® PCR Media will be taken from a minimum of 500 symptomatic individuals with a clinical presentation consistent with vaginitis,...
What is the current status of trial NCT06975436?
This trial is currently completed. The enrollment target is 738 participants. The study started on 2024-12-30. Estimated completion is 2025-06-30.
What conditions does trial NCT06975436 study?
This clinical trial studies the following conditions: Bacterial Vaginosis, Candida Vaginitis.
What interventions are being tested in trial NCT06975436?
The interventions under investigation include: cobas® BV/CV test (DIAGNOSTIC_TEST), BD Max™ Vaginal Panel (DIAGNOSTIC_TEST), Cepheid Xpert Xpress MVP (DIAGNOSTIC_TEST), Hologic Aptima BV Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06975436?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06975436 being conducted?
This trial has 10 study locations across California, Colorado, Florida, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Vaginosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Protocol CERN Feasibility Study
RECRUITING · NA
-
Prospective Data Bank Creation to Study Vaginal Conditions
RECRUITING
-
Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome
RECRUITING · Early Phase 1
-
Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs
ACTIVE NOT RECRUITING · Phase 2
-
Treatment of Bacterial Vaginosis (BV) With Tinidazole
COMPLETED · Phase 4
-
Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.